Moderna
Open
$47.02
Prev. Close
$47.01
High
$47.02
Low
$47.00
Market Snapshot
$17.86B
-6.3
-9.28
$3.24B
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
emptyResult
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Recently from Cashu
Moderna Stock Drops 8% Amid FDA Leadership Change and Vaccine Approval Uncertainty
Moderna Faces Uncertainty Following Regulatory Leadership Change Moderna, a leading biotechnology firm, experiences heightened scrutiny following the resignation of Peter Marks, the FDA's prominent va…
Moderna Faces Uncertainty as FDA Vaccine Regulator Resigns Amid Public Health Controversies
FDA Shake-Up Poses Challenges for Vaccine Manufacturers The recent resignation of Peter Marks, the FDA's leading vaccine regulator, sends shockwaves through the biotech sector, particularly impacting…
Moderna Faces Uncertainty After FDA Regulator Resignation Amid Vaccine Oversight Concerns
Regulatory Shift Raises Concerns for Vaccine Innovators The resignation of Peter Marks, the FDA's top vaccine regulator, sends shockwaves through the biotech industry, particularly affecting companies…
Moderna Faces Major Challenges Amidst Market Volatility and Economic Uncertainty
Moderna Faces Significant Challenges Amid Market Volatility In the current financial landscape, the biotechnology sector, particularly companies like Moderna, grapples with substantial hurdles that ex…